Enanta Pharma officer forfeits shares for RSU tax withholding

Enanta Pharmaceuticals’ chief business officer reported a small share withholding related to previously granted equity.

Rhea-AI Filing Summary

Enanta Pharmaceuticals’ chief business officer reported a small share withholding related to previously granted equity. On 12/01/2025, 498 shares of Enanta common stock were forfeited at $14.12 per share to cover withholding taxes from the settlement of a portion of a restricted stock unit award granted on November 19, 2021.

After this tax-related share forfeiture, the officer beneficially owns 39,723 shares of Enanta common stock in direct ownership. The transaction reflects routine equity compensation and tax settlement activity for a senior executive.

Insider Trade Summary

Exercise Price or Tax Liability: 498 shares

Exercise Price or Tax Liability 1 txn

Insider Luu Brendan

Role Chief Business Officer

Type	Security	Shares	Price	Value
Exercise Price or Tax Liability	Common Stock	498	$14.12	$7K

Holdings After Transaction: Common Stock — 39,723 shares (Direct)

Footnotes (1)

1. F1. Represents the number of shares of ENTA common stock forfeited by the reporting person to cover withholding taxes due as a result of settlement of a portion of the restricted stock unit award granted on November 19, 2021.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did ENANTA PHARMACEUTICALS INC (ENTA) report?

An Enanta Pharmaceuticals chief business officer reported the forfeiture of 498 shares of common stock to cover taxes due on a restricted stock unit settlement.

When did the ENTA executive’s share forfeiture occur?

The tax-related share forfeiture for the Enanta Pharmaceuticals officer took place on 12/01/2025.

At what price were the Enanta (ENTA) shares valued in this Form 4 transaction?

The 498 forfeited shares of Enanta common stock were valued at $14.12 per share for the tax withholding transaction.

How many ENTA shares does the officer own after this transaction?

Following the reported tax withholding forfeiture, the officer beneficially owns 39,723 shares of Enanta Pharmaceuticals common stock directly.

What was the source of the restricted stock units involved for ENTA?

The shares were forfeited to cover taxes arising from settlement of a portion of a restricted stock unit award granted on November 19, 2021.

What is the reporting person’s role at Enanta Pharmaceuticals (ENTA)?

The reporting person serves as an officer of Enanta Pharmaceuticals, with the title Chief Business Officer.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 12/03/2025 - 05:02 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Luu Brendan

(Last) (First) (Middle)

C/O ENANTA PHARMACEUTICALS, INC.

4 KINGSBURY AVENUE

(Street)

WATERTOWN MA 02472

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
ENANTA PHARMACEUTICALS INC [ ENTA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Business Officer

3. Date of Earliest Transaction (Month/Day/Year)
12/01/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	12/01/2025		F		498(1)	D	$14.12	39,723	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents the number of shares of ENTA common stock forfeited by the reporting person to cover withholding taxes due as a result of settlement of a portion of the restricted stock unit award granted on November 19, 2021.

	/s/ Matthew Kowalsky as attorney-in-fact	12/03/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.